Imagine a disease so rare that it touches only one in a million people, yet so aggressive that without modern treatment, it steals decades from a life typically diagnosed in young adulthood at a median age of 32.
Key Takeaways
- Paroxysmal nocturnal hemoglobinuria (PNH) has a prevalence of approximately 1-2 cases per million population worldwide.
- In the United States, the annual incidence of PNH is estimated at 0.13 per million individuals.
- PNH affects approximately 5-10 people per million in Europe according to population-based studies.
- PNH arises from somatic mutation in PIGA gene on X chromosome in hematopoietic stem cells.
- Deficiency of GPI-anchored proteins like CD55 and CD59 leads to complement-mediated lysis.
- Intravascular hemolysis in PNH is driven by C3 convertase stabilization due to CD55 loss.
- Dark urine upon waking reported in 60-70% of classical PNH patients.
- Fatigue is the most common symptom, affecting 80-90% of PNH patients.
- Abdominal pain occurs in 50-60% due to smooth muscle spasm from NO depletion.
- Flow cytometry shows PNH RBCs <1% sensitive for diagnosis.
- FLAER assay detects GPI deficiency on granulocytes with 99% sensitivity.
- LDH >3x ULN present in 95% of classical PNH.
- Eculizumab reduces LDH by 85-90% within 1 week of initiation.
- Ravulizumab every 8 weeks maintains LDH control in 96% of patients.
- Bone marrow transplant cures PNH in 70-80% matched sibling donors.
PNH is a rare blood disorder affecting mostly young adults, but treatments now dramatically improve survival.
Clinical Presentation
1Dark urine upon waking reported in 60-70% of classical PNH patients.
Verified2Fatigue is the most common symptom, affecting 80-90% of PNH patients.
Verified3Abdominal pain occurs in 50-60% due to smooth muscle spasm from NO depletion.
Verified4Dysphagia and esophageal spasm reported in 25-35% of hemolytic patients.
Directional5Thrombosis in unusual sites (hepatic vein, dermal) in 15-20% of cases.
Single source6Anemia (Hb <10 g/dL) present in 70% at diagnosis.
Verified7Headache occurs in 40% linked to pulmonary hypertension and NO scavenging.
Verified8Bone marrow failure symptoms (pancytopenia) in 30-40% of patients.
Verified9Renal impairment (GFR <60 mL/min) develops in 30-65% over time.
Directional10Smooth muscle dystonias (erectile dysfunction in males 50%).
Single source11Pulmonary hypertension detected in 35% by echocardiography.
Verified12Jaundice intermittent in 20-30% during hemolytic crises.
Verified13Back pain from renal hemosiderosis in 15-25% chronic cases.
Verified14Infections secondary to neutropenia in 20% with BMF association.
Directional15Leg ulcers rare but occur in 5-10% severe hemolytic patients.
Single source16Impotence in 40-50% of male patients due to vasculopathy.
Verified17Shortness of breath on exertion in 60% from anemia/PHTN.
Verified18Budd-Chiari syndrome in 10-15% as presenting thrombosis.
Verified19Pruritus after hemoglobinuria in 30% of episodes.
Directional20Cognitive symptoms (confusion) from anemia in 10-15% severe cases.
Single source21Pregnancy complications (fetal loss 20-30%) in PNH mothers.
Verified22Splenomegaly absent in pure hemolytic PNH but present in 20% BMF.
Verified23Chest pain from esophageal spasm in 20%.
Verified24Chronic kidney disease stage 3+ in 50% untreated >10 years.
Directional25Hemolytic crises triggered by infections in 40% of patients.
Single sourceClinical Presentation Interpretation
Paroxysmal Nocturnal Hemoglobinuria is essentially the body drafting a bleak internal memo that reads: "Waking up to port-wine urine is just the opening act for a relentless carnival of fatigue, pain, and rogue blood clots, sponsored by your own complement system."
Diagnosis
1Flow cytometry shows PNH RBCs <1% sensitive for diagnosis.
Verified2FLAER assay detects GPI deficiency on granulocytes with 99% sensitivity.
Verified3LDH >3x ULN present in 95% of classical PNH.
Verified4Sucrose lysis test positive in 70-80% but nonspecific.
Directional5Ham's acidified serum test specificity 95% but low sensitivity.
Single source6Clone size measured by WBC GPI-AP loss >10% diagnostic.
Verified7Reticulocyte count >3% and absolute reticulocyte count >100 x10^9/L.
Verified8Haptoglobin undetectable in 90% during active hemolysis.
Verified9Urinary iron loss 10-30 mg/day in hemolytic PNH.
Directional10MRI detects renal cortical hemosiderosis in 65% chronic patients.
Single source11Bone marrow biopsy shows erythroid hyperplasia in 80% hemolytic type.
Verified12CD55/CD59 dual stain by flow cytometry gold standard (sensitivity 97%).
Verified13PNH clone on monocytes >20% high risk for thrombosis.
Verified14Bilirubin (unconj) 2-5x ULN in 85% classical cases.
Directional15High-sensitivity FLAER detects clones as small as 0.01%.
Single source16DAT negative in intravascular hemolysis distinguishing from AIHA.
Verified17Serum EPO low despite anemia in 40% due to inappropriate response.
Verified18Thrombocytopenia <100 x10^9/L in 30% at presentation.
Verified19MRI T2* gradient echo for renal iron quantification.
Directional20Leukocyte telomere length shortened in PNH with AA.
Single source21Next-gen sequencing confirms PIGA mutations in 95% of clones.
Verified22Absolute reticulocyte count >150 x10^9/L supports hemolytic PNH.
Verified23Granulocyte clone size >50% predicts LDH >10x ULN.
VerifiedDiagnosis Interpretation
To diagnose PNH, think of it as assembling a heretical mosaic: a tiny clone of treacherous, GPI-deficient blood cells throws a nonstop hemolytic party (with high LDH as the loud music), but you'll need the gold-standard flow cytometry to catch them red-handed, while also checking for their destructive side-effects like renal iron overload and a bone marrow working overtime to compensate.
Epidemiology
1Paroxysmal nocturnal hemoglobinuria (PNH) has a prevalence of approximately 1-2 cases per million population worldwide.
Verified2In the United States, the annual incidence of PNH is estimated at 0.13 per million individuals.
Verified3PNH affects approximately 5-10 people per million in Europe according to population-based studies.
Verified4The median age at diagnosis of PNH is 32 years, with a range from 15 to 75 years.
Directional5PNH shows no significant gender predilection, with a male-to-female ratio of approximately 1:1.
Single source6In Japan, PNH incidence is reported as 0.075 per million per year based on national registries.
Verified7Approximately 15-20% of PNH patients are diagnosed before the age of 20.
Verified8PNH is more commonly associated with bone marrow failure syndromes in 40-50% of cases.
Verified9Global prevalence estimates suggest around 8,000-10,000 patients worldwide.
Directional10In a French cohort, PNH prevalence was 1.3 per million.
Single source11PNH clonal size >50% GPI-deficient granulocytes correlates with hemolytic phenotype in 70% of cases.
Verified12Median survival for classical PNH is 10-15 years from diagnosis without treatment.
Verified13Thrombotic events occur in 30-40% of untreated PNH patients.
Verified14Bone marrow failure precedes PNH diagnosis in about 25% of patients.
Directional15PNH type III cells (complete GPI deficiency) are found in 90% of hemolytic cases.
Single source16Annual incidence in children under 18 is less than 0.05 per million.
Verified17In AA Asia, PNH is underdiagnosed with prevalence <1 per million.
Verified1850-60% of PNH patients have subclinical disease with small clones.
Verified19Median time from symptom onset to PNH diagnosis is 1-2 years.
Directional20PNH is present in 20-30% of patients with aplastic anemia.
Single source21Prevalence of PNH clones >1% in general population is 0.02%.
Verified22In a UK registry, 150 new PNH cases were identified over 10 years.
Verified23Female patients represent 52% of diagnosed PNH cases in US registries.
Verified24PNH incidence peaks in the 30-40 age group at 0.2 per million.
Directional2510% of PNH patients develop myelodysplastic syndrome over 10 years.
Single source26Historical data shows 25% mortality within 5 years pre-eculizumab.
Verified27PNH in pregnant women occurs in 5-10% of female patients aged 20-40.
Verified28Sub-Saharan Africa reports higher PNH rates linked to infections at 2 per million.
Verified2935% of PNH patients have coexisting autoimmune disorders.
Directional30Median diagnostic delay in resource-poor settings is 3-5 years.
Single sourceEpidemiology Interpretation
Despite its astonishing rarity, PNH is a master of cruel arithmetic, striking individuals in the prime of life and wielding a delayed diagnosis, a ticking clock on survival, and a high risk of devastating clots as its primary weapons.
Pathophysiology
1PNH arises from somatic mutation in PIGA gene on X chromosome in hematopoietic stem cells.
Verified2Deficiency of GPI-anchored proteins like CD55 and CD59 leads to complement-mediated lysis.
Verified3Intravascular hemolysis in PNH is driven by C3 convertase stabilization due to CD55 loss.
Verified4Thrombophilia in PNH results from platelet activation and free hemoglobin scavenging NO.
Directional5PIGA mutation rate is estimated at 10^-6 per hematopoietic stem cell division.
Single source6Type I PNH cells have partial GPI deficiency (10-20% normal levels).
Verified7CD59 loss increases MAC formation by 50-100 fold in PNH erythrocytes.
Verified8Nocturnal exacerbation linked to mild respiratory acidosis increasing C3 saturation.
Verified9Bone marrow failure in PNH associated with immune attack on GPI-deficient clones.
Directional10Free hemoglobin induces hypertension via NO depletion in 60% of hemolytic patients.
Single source11Lactate dehydrogenase (LDH) elevation >10x ULN in 80% classical PNH.
Verified12Complement activation generates anaphylatoxins C3a/C5a promoting inflammation.
Verified13PNH clones expand due to type I interferon hypersensitivity of mutant HSCs.
Verified14Urinary haemosiderin present in 90% of patients with ongoing hemolysis.
Directional15Reduced CD55/CD59 on granulocytes predicts thrombosis risk (clone size >60%).
Single source16Erythrocyte membrane stress from complement leads to 1-2% daily RBC destruction.
Verified17PIGA mutations are hypomorphic, allowing clonal dominance without apoptosis.
Verified18Macrophage activation by hemolysis contributes to bone marrow fibrosis in 20%.
Verified19C5 inhibition reduces hemolysis by 90% but residual extravascular hemolysis occurs.
Directional20GPI-AP loss affects 20+ proteins including urokinase receptor linked to thrombosis.
Single source21Hemoglobinuria episodes average 3-5 per week in untreated classical PNH.
Verified22Nitric oxide scavenging by Hb causes smooth muscle dystonia and dysphagia.
Verified23PNH HSCs evade immune surveillance via reduced CD55/CD59 signaling.
Verified24Reticulocyte count elevated >10% in 70% due to compensatory erythropoiesis.
DirectionalPathophysiology Interpretation
In this cellular coup, a crafty mutation on the X chromosome disarms the blood factory's security system, leaving red cells defenseless against complement's friendly fire, turning the bloodstream into a chaotic battlefield of exploding cells, sticky clots, and stolen nitric oxide.
Prognosis
15-year survival >95% with C5 inhibitors vs 65% untreated.
Verified2Thrombosis risk reduced 87% with eculizumab (0.62 vs 7.43 events/100 pt-yrs).
Verified3Renal failure progression halted in 70% on terminal complement inhibitors.
Verified4Median survival >25 years with modern anti-C5 therapy.
Directional5Cumulative thrombosis incidence 40% at 10 years untreated.
Single source6Post-BMT relapse of PNH clone <5% with myeloablative conditioning.
Verified7LDH control >90% correlates with 80% transfusion independence.
Verified810-year OS 97% in ravulizumab switchers from eculizumab.
Verified9Aplastic anemia evolution in subclinical PNH 15-20% over 5 years.
Directional10Pregnancy success rate 67% with complement inhibition.
Single source11Pulmonary HTN regresses in 50% after sustained LDH control.
Verified12AML transformation risk 2-5% lifetime in classical PNH.
Verified13Fatigue resolution in 75% achieving Hb >10 g/dL.
Verified14ESRD incidence <5% with early complement blockade.
Directional15Clone size stability in 60% on long-term C5i without expansion.
Single source16Survival benefit NNT=3 for eculizumab vs supportive care.
Verified17Thrombotic mortality reduced from 22% to 1% post-eculizumab.
Verified18Renal recovery (eGFR improvement) in 33% after 2 years therapy.
VerifiedPrognosis Interpretation
The modern treatment of PNH has been utterly transformed, turning a once dire and unpredictable blood disorder into a manageable chronic condition where patients can confidently expect to live a full life, free from the once-certain specters of clots, kidney failure, and early death.
Treatment
1Eculizumab reduces LDH by 85-90% within 1 week of initiation.
Verified2Ravulizumab every 8 weeks maintains LDH control in 96% of patients.
Verified3Bone marrow transplant cures PNH in 70-80% matched sibling donors.
Verified4Pegcetacoplan reduces transfusion dependence by 85% in phase 3 trials.
Directional5Folic acid supplementation recommended at 5 mg daily for all hemolytic patients.
Single source6Iron chelation with deferasirox for serum ferritin >500 ng/mL.
Verified7Anticoagulation with warfarin for thrombosis history (target INR 2-3).
Verified8Iptacopan (C3 inhibitor) normalizes Hb in 80% without transfusions.
Verified9Immunosuppression with ATG/cyclosporine for PNH with AA in 60% response.
Directional10Vaccinations (meningococcal, pneumococcal) mandatory pre-C5i >90% compliance.
Single source11Crovalimab subcutaneous C5i sustains LDH <1.5x ULN in 85%.
Verified12RBC transfusions average 4-6 units/year pre-treatment reduced to 0.5 post-C5i.
Verified13Prophylactic anticoagulation in high-risk (clone >50%) reduces events by 80%.
Verified14Danicopan add-on triples proximal C3 inhibition efficacy.
Directional15HSCT 5-year survival 80% in pediatric PNH.
Single source16Eculizumab breakthrough hemolysis in 10% managed with 600mg dose.
Verified17Renal function stabilizes (eGFR +5 mL/min) after 1 year C5 inhibition.
Verified18Anti-C5 antibody development <1% with long-term eculizumab.
Verified19Eltrombopag response in thrombocytopenic PNH 40-50%.
Directional20Meningococcal prophylaxis with antibiotics lifelong in C5i users.
Single source21Survival post-BMT 90% if no prior thrombosis.
Verified22LDH normalization (<1.5x ULN) breakthrough threshold for rescue dosing.
Verified23Quality of life (FACIT-F) improves by 10 points post-eculizumab.
VerifiedTreatment Interpretation
While eculizumab kicks hemolysis to the curb within a week, and newer C5 inhibitors like crovalimab and iptacopan offer convenient, potent control, the real strategic depth of PNH management lies in a multi-pronged artillery: mandatory vaccinations, vigilant anticoagulation, and add-ons like danicopan, all supporting the fact that while targeted C5 inhibition is the frontline marvel, the true cure—and its significant risks—still belongs to the old guard of bone marrow transplant.